What is the registration number for TULIPIA TRIAL USING BIM23A760 DOSE LEVELS IN PATIENTS IN ACROMEGALY?

TULIPIA TRIAL USING BIM23A760 DOSE LEVELS IN PATIENTS IN ACROMEGALY is registered under USPTO registration number 0.

TUL

USPTO Trademark Record

ABANDONED

TULIPIA TRIAL USING BIM23A760 DOSE LEVELS IN PATIENTS IN ACROMEGALY

Q: Who owns the TULIPIA TRIAL USING BIM23A760 DOSE LEVELS IN PATIENTS IN ACROMEGALY trademark?

The TULIPIA TRIAL USING BIM23A760 DOSE LEVELS IN PATIENTS IN ACROMEGALY trademark is owned by IPSEN PHARMA S.A.S..

Q: What class is the TULIPIA TRIAL USING BIM23A760 DOSE LEVELS IN PATIENTS IN ACROMEGALY trademark registered in?

The TULIPIA TRIAL USING BIM23A760 DOSE LEVELS IN PATIENTS IN ACROMEGALY trademark is registered in Class 042 (Scientific, technology & SaaS services).

Q: What is the serial number for TULIPIA TRIAL USING BIM23A760 DOSE LEVELS IN PATIENTS IN ACROMEGALY?

The USPTO serial number for TULIPIA TRIAL USING BIM23A760 DOSE LEVELS IN PATIENTS IN ACROMEGALY is 79089155.

SN 79089155·Reg 0·Filed Oct 14, 2010

Owner IPSEN PHARMA S.A.S.

Scientific and technological services and research and design relating thereto; industrial analysis, industrial research and industrial design services; quality control and authentication services; design and development of computer hardware and software.

TULIPIA TRIAL USING BIM23A760 DOSE LEVELS IN PATIENTS IN ACROMEGALY (Serial No. 79089155), Registration No. 0, is a abandoned US trademark filed on Oct 14, 2010 by IPSEN PHARMA S.A.S.. This trademark covers Class 042 (Scientific, technology & SaaS services).

Mark Intelligence

TULIPIA TRIAL USING BIM23A760 DOSE LEVELS IN PATIENTS IN ACROMEGALY (Reg. #0) is an abandoned US trademark that was filed in 2010 but has since been abandoned. The mark covers Class 042 (Scientific, technology & SaaS services). Goods and services include Scientific and technological services and research and design relating thereto; industrial analysis, industrial research.... The mark faced 3 opposition proceedings during prosecution.

FILED

Oct 14, 2010

SERIAL

79089155

REG#

Owner

Applicant

IPSEN PHARMA S.A.S.

Entity

Not Provided

Address

65 quai Georges Gorse, F-92100 BOULOGNE BILLANCOURT

Country

Attorney

Law firm

Bernard-Boyle Hélène

Address

65, quai Georges Gorse, F-92100 Boulogne-Billancourt, , FRANCE

Get pre-filing clearance

AI attorney analyzes your proposed mark against USPTO — Go/No-Go verdict, class-by-class risks, and strategy recommendations.

Run clearance

Filing Information

StatusABANDONED

Filing DateOct 14, 2010

Serial Number79089155

Registration No.0

Status DateOct 14, 2020

Mark TypeStandard characters

Status DescriptionUS application is dead and abandoned

Filing Signals

FILED

2010

YEARS AGO

16y

CLASSES

MADRID FILINGS

—

Opposed 3× during prosecution

Search 14M+ trademarks

Free USPTO lookups by name, owner, or serial number. No account needed.

Search now

Full Goods & Services

CLASSES

OFFICE

USPTO

COUNTRY

Class 042Scientific, technology & SaaS services

US codes: 100, 101

This description is as filed with the USPTO and defines the scope of trademark protection.

Status History

20 events

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED

Nov 14, 2021

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED

DEATH OF INTERNATIONAL REGISTRATION

Nov 13, 2021

DEATH OF INTERNATIONAL REGISTRATION

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

Nov 24, 2012

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

FINAL DECISION TRANSACTION PROCESSED BY IB

Aug 31, 2012

FINAL DECISION TRANSACTION PROCESSED BY IB

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

Aug 10, 2012

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

FINAL DISPOSITION NOTICE SENT TO IB

Aug 10, 2012

FINAL DISPOSITION NOTICE SENT TO IB

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

Apr 25, 2012

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

Apr 25, 2012

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE

Aug 10, 2011

ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE

ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND

Aug 10, 2011

ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND

UNDELIVERABLE MAIL - NO ACTION TAKEN

Mar 02, 2011

UNDELIVERABLE MAIL - NO ACTION TAKEN

REFUSAL PROCESSED BY IB

Jan 29, 2011

REFUSAL PROCESSED BY IB

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

Jan 10, 2011

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

Jan 07, 2011

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

REFUSAL PROCESSED BY MPU

Jan 07, 2011

REFUSAL PROCESSED BY MPU

NON-FINAL ACTION WRITTEN

Jan 06, 2011

NON-FINAL ACTION WRITTEN

ASSIGNED TO EXAMINER

Jan 05, 2011

ASSIGNED TO EXAMINER

APPLICATION FILING RECEIPT MAILED

Nov 30, 2010

APPLICATION FILING RECEIPT MAILED

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Nov 26, 2010

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

SN ASSIGNED FOR SECT 66A APPL FROM IB

Nov 25, 2010

SN ASSIGNED FOR SECT 66A APPL FROM IB

TULIPIA TRIAL USING BIM23A760 DOSE LEVELS IN PATIENTS IN ACROMEGALY

Get pre-filing clearance

Search 14M+ trademarks

Run a conflict check

Other Marks by IPSEN PHARMA S.A.S.

Other Marks in Class 042 — Scientific, technology & SaaS services

Resources

Company